Stryker, DaVita And These 2 ETFs: CNBC's 'Final Trades'

On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named the  SPDR S&P Biotech ETF XBI, saying if you "want growth, you can find it in health care, it’s reasonably priced," specifically in biotech.

Shannon Saccocia of Boston Private said Stryker Corporation SYK is a growth play in medical instruments and equipment. Procedures will "continue to accelerate," she added.

Don’t forget to check out our premarket coverage here.

Brian Brooks, Bitfury CEO, named Invesco DB US Dollar Index Bullish Fund UUP as his final trade.

Joseph Terranova of Virtus Investment Partners said DaVita Inc. DVA is trading at 11 times earnings and has 95% U.S. revenue exposure.

Check This Out: NVIDIA, Micron Technology Club And 2 Other Stocks Insiders Are Selling

Photo via Shutterstock.